Adjuvant treatment for early-stage endometrial cancer

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 245-255

  Zighelboim, Israel ^a   Powell, Matthew A ^a  

^a MO   (United States)

Author keywords

adjuvant; biologic therapy; chemotherapy; early stage; Endometrial cancer; radiotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CATHEPSIN B; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; HERMES ANTIGEN; HYDROXYPROGESTERONE CAPROATE; INDOLEAMINE; IXABEPILONE; P CADHERIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BNIP3; SYNDECAN 1; TEMSIROLIMUS; UROKINASE RECEPTOR; UVOMORULIN; VASCULOTROPIN; VERSICAN;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COST OF ILLNESS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; EARLY CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MISMATCH REPAIR; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RISK MANAGEMENT; SALPINGOOOPHORECTOMY; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT;

EID: 79955565986     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318218c5b8     Document Type: Article

References (21)

1. Altekruse SF, Kosary CL, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/ 1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Morrow CP, Bundy BN, Kruman RJ, et al. Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40: 55-65.
3. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.
4. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419-427. (Pubitemid 10018299)
5. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404-1411. (Pubitemid 30215963)
6. Keys HM, Roberts JA, Brunetto VL, et al; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92: 744-751. (Pubitemid 38251372)
7. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984; 3:825-832. (Pubitemid 14105231)
8. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: longterm outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005; 63:834-838. (Pubitemid 41400072)
9. Rankins NC, Secord AA, Jewell E, et al. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer. Gynecol Oncol. 2007;106:388-393. (Pubitemid 47087940)
10. Morrow CP, Bundy B, Homesley H, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial cancer, stage I and occult stage II: aGOGstudy. Gynecol Oncol. 1990;36:166-171. (Pubitemid 20061279)
11. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166. (Pubitemid 41095150)
12. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44. (Pubitemid 46630491)
13. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy versus radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer. 2006;95:266-271. (Pubitemid 44187586)
14. Susumu N, Sagae S, Udagawa Y, et al; Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226-233. (Pubitemid 350299451)
15. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422-2431.
16. Homesley H, Filiaci V, Gibbons SK, et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: aGynecologicOncologyGroup study. Gynecol Oncol. 2009;112:543-552.
17. Vergote I, Kjørstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989;64:1011-1016. (Pubitemid 19208849)
18. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964-978. (Pubitemid 47414814)
19. Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab inthe treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol Proc Am Soc Clin Oncol. 2009;27:(15S)-5531.
20. Oza AM, Elit L, Provencher J, et al. Phase II study of CCI-779 (temsirolimus) in patients with metastatic and/or locally advanced recurrent endometrial cancer. J Clin Oncol Proc Am Soc Clin Oncol. 2008;26:(15S)-5516.
21. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol. 2009;27: 3104-3108.